Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 9,433-9,444 of 23,847
Drug study icon
OngoingEUCTR 2022-001666-35

Safety study of KarXT in schizophrenia

This study is ongoing in Bulgaria. It is testing KarXT for schizophrenia.

In Bulgaria
SchizophreniaOther
Countries
Bulgaria
Sponsor
Karuna Therapeutics, Inc.
Condition
Schizophrenia
Drug study icon
TerminatedNCT05254405

An Open Label Study of IV Brexanolone for PTSD

This summary needs review. Please check the official study record and contact the research team for details.

In Austin
PTSDDrugFrom 18 Years to 50 Years
Countries
United States
Sponsor
Donald Jeffrey Newport
Condition
PTSD
Drug study icon
CompletedNCT00814957

GSK618334 for Addiction

This study is completed in the United Kingdom. It is testing GSK618334 for Addiction.

In Harrow
AddictionDrugFrom 30 Years to 55 Years
Countries
United Kingdom
Sponsor
GlaxoSmithKline
Condition
Addiction
Drug study icon
Active Not RecruitingNCT04433858

Safety and Efficacy of Psilocybin for treatment-resistant depression

This study is active but not recruiting in the United States. It is testing safety and Efficacy of Psilocybin for treatment-resistant depression.

Multiple locations, including Palo Alto
DepressionDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Sheppard Pratt Health System
Condition
Depression
Drug study icon
CompletedNCT01666119

Safety study of BEMA® Buprenorphine NX in Addiction

This study is completed in the United States. It is testing BEMA® Buprenorphine NX for Addiction.

Multiple locations, including Birmingham
AddictionDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
BioDelivery Sciences International
Condition
Addiction
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.